Departure. Clinical Miss. Billion: Should You Bet on Pfizer?
Pfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
Implementing zero based budgeting strategies can lead to lasting financial stability. Uncover methods to ensure your budgeting supports long-term goals.
27,791 articlesPfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
Grail stock surged on hype around early cancer-detection tests, then faded after a mixed trial result. This article a...
A bold alliance between Allseas and a mining innovator aims to commercialize deep-sea nodule recovery. This strategic...
Two popular ETFs populate the healthcare investing scene: PPH focuses narrowly on drugmakers, while IXJ spans the bro...
A little-known aerospace stock has delivered a blistering 470% gain over five years and recently reached a fresh all-...
Big funds sometimes trim stakes in the market's most valuable names. This article breaks down why institutional inves...
The quantum race isn’t just about flashy qubit players. The real upside sits in the infrastructure that makes quantum...
The gene-editing field is maturing from hype to real profits. This article outlines why a broader set of players coul...
Macerich faces a retail landscape that’s evolved in 2025. This deep dive breaks down the factors shaping macerich (ma...
Grail stock faced another sharp move as trial news weighed on sentiment. This guide unpacks why the slump happened, w...
Orbital refueling could change the game for long-distance space missions. This deep dive looks at how NASA and Rocket...
Gossamer Bio's 2026 earnings outlook centers on cash runway, pipeline progress, and strategic partnerships. This arti...